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Abstract
While natural CD4
+Foxp3
+ regulatory T (nTREG) cells have long been viewed as a stable and distinct lineage that is
committed to suppressive functions in vivo, recent evidence supporting this notion remains highly controversial. We sought
to determine whether Foxp3 expression and the nTREG cell phenotype are stable in vivo and modulated by the inflammatory
microenvironment. Here, we show that Foxp3
+ nTREG cells from thymic or peripheral lymphoid organs reveal extensive
functional plasticity in vivo. We show that nTREG cells readily lose Foxp3 expression, destabilizing their phenotype, in turn,
enabling them to reprogram into Th1 and Th17 effector cells. nTREG cell reprogramming is a characteristic of the entire
Foxp3
+ nTREG population and the stable Foxp3
NEG TREG cell phenotype is associated with a methylated foxp3 promoter. The
extent of nTREG cell reprogramming is modulated by the presence of effector T cell-mediated signals, and occurs
independently of variation in IL-2 production in vivo. Moreover, the gut microenvironment or parasitic infection favours the
reprogramming of Foxp3
+ TREG cells into effector T cells and promotes host immunity. IL-17 is predominantly produced by
reprogrammed Foxp3
+ nTREG cells, and precedes Foxp3 down-regulation, a process accentuated in mesenteric sites. Lastly,
mTOR inhibition with the immunosuppressive drug, rapamycin, stabilizes Foxp3 expression in TREG cells and strongly
inhibits IL-17 but not RORct expression in reprogrammed Foxp3
2 TREG cells. Overall, inflammatory signals modulate mTOR
signalling and influence the stability of the Foxp3
+ nTREG cell phenotype.
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Introduction
Naturally-occurring regulatory T (nTREG) cells are a central
component of peripheral tolerance as they maintain normal
immune homeostasis [1,2,3]. Originally defined by high expression
of CD25 (a subunit of the IL-2 receptor) [4], nTREG cells are now
primarily characterized by expression of the transcription factor
Foxp3 [5,6,7,8]. Stable expression of Foxp3 is essential for the
development, homeostasis and suppressive function of nTREG cells
[8,9]. Functional abrogation of Foxp3 in mice (scurfy mice) and
humans (IPEX syndrome) leads to the development of lethal multi-
organ autoimmune and inflammatory diseases [10,11,12]. On the
other hand, forced expression of Foxp3 in conventional
CD4
+CD25
2 T cells is sufficient for the acquisition of suppressive
activity in vitro and in vivo [5,6,7,13]. Furthermore, the analysis of
GFP knock-in, Foxp3 deficient mice revealed that the absence of
Foxp3 protein abrogates nTREG suppressive activity, but is
dispensable for the maintenance of nTREG cell anergic phenotype
[14].
The notion that Foxp3
+ TREG cells represent a stable,
terminally-differentiated lineage has been recently addressed.
The transient nature of Foxp3 expression in induced TREG
(iTREG) cells in vitro [15] combined with the potential of Foxp3
+
nTREG cells to differentiate into Th17 cells in the presence of IL-6
and TGF-b [16,17,18] suggested that Foxp3-expressing TREG cell
subsets manifest functional adaptation under certain conditions at
least in vitro. Recent studies reported the down-regulation of Foxp3
expression in nTREG cells in vivo under lymphopenic conditions
[19,20,21] or in organ-specific autoimmunity [22]. Although these
reports highlight the functional plasticity of the Foxp3
+ nTREG cell
lineage, more recent studies argue against this phenomenon and
propose that Foxp3
+ TREG cells are refractory to this functional
reprogramming [23,24]. As TREG cell-based therapy is proposed
as a treatment in autoimmune and transplantation settings, it is
critical to assess the stability of Foxp3
+ TREG cells and dynamics of
there function or reprogramming under inflammatory conditions.
Recent evidence clearly identifies the mammalian target of
rapamycin (mTOR), a conserved serine-threonine protein kinase
inhibited by the immunosuppressive drug rapamycin, as a master
metabolic regulator that integrates environmental cues from
nutrients, growth factors and stress conditions to drive cell growth,
proliferation and T cell differentiation. More specifically, inhibi-
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rapamycin treatment, promotes TREG differentiation [25,26,27]
while blunting Th17 differentiation and function in vitro and in vivo
[28]. Currently, the role of mTOR signalling in the process of
nTREG cell reprogramming is not well understood.
In this study, we show that the stability of Foxp3
+ nTREG cell
phenotype and function is a dynamic process modulated by
inflammatory signals. Thymic or peripheral Foxp3
+ nTREG cells
manifest prominent functional plasticity and readily reprogram
into Th1 and Th17 effector cells, particularly in the gut
microenvironment or sites of parasitic infection. nTREG cell
reprogramming is a characteristic of the entire Foxp3
+ nTREG
population and the stable, reprogrammed TREG cell phenotype is
associated with a methylated foxp3 promoter. The extent of nTREG
cell reprogramming is modulated by effector T (TEFF) cell-
mediated signals but occurs independently of IL-2 dose variations
in vivo. Reprogrammed Foxp3
+ TREG cells predominantly produce
IL-17, the expression of which precedes Foxp3 down-regulation, a
process promoted in the intestinal microenviroment. Lastly, we
report a mechanism whereby mTOR inhibition by rapamycin,
stabilizes Foxp3 expression and prevents nTREG cell reprogram-
ming into Th1/Th17 effectors in vivo. Thus, inflammatory signals
may modulate mTOR function and impact the stability of the
Foxp3
+ TREG cell phenotype.
Materials and Methods
Mice
WT, TCRb
2/2 and Ly5.1 congenic C57BL/6 mice were
obtained from Taconic Laboratories, GFP transgenic C57BL/6
(GFPtg) mice were provided by C. Schaefer [29], Foxp3
GFPki mice
were obtained from A. Rudensky (Memorial Sloan-Kettering
Cancer Center) and Ly5.1 Foxp3
GFPki congenic line were
generated in our laboratory. All mice were bred and maintained
in a specific pathogen-free animal facility at McGill University.
T cell subsets purification and adoptive transfer
Various CD4
+ T cell subsets were separated from AutoMACS-
enriched CD4
+ T cells using a FACSAria
TM Cell Sorter (BD)
(purity .98%) or the autoMACS Cell Sorter (Miltenyi Biotec)
(purity ranging 85–95%), as described previously [30]. For
adoptive transfer studies, T cell subsets were transferred i.v. into
TCRb
2/2 or RAG2
2/2 recipient mice. For adoptive transfer
studies, T cell subsets were transferred i.v. into TCRb
2/2 or
RAG2
2/2 recipient mice.
Lymphocyte isolation from lamina propria
To isolate lymphocytes from lamina propria (LP), a protocol
from Weigmann et al. was used [31].
Antibodies and flow cytometry
For surface phenotyping the following mAbs were used: anti-
CD4 (RM4–5), anti-CD25 (PC61), anti-CD3 (145-2C11) and anti-
Ly5.1 (A120) (eBioscience or BD Bioscience). The expression of
Foxp3 (PJK-16s) (e-Bioscience) and Ki-67 (B56) (BD Bioscience)
was determined by intracellular staining performed according to
the manufactures protocol (e-Bioscience). To determine the
cytokine production, lymphocytes were re-stimulated for 4 hrs at
37uC with PMA (20 ng/ml), ionomycin (1 nM) and BD
GolgyStop
TM (1:1000 dilution) and then stained intra-cellular
with anti-IFN-c (XMG1.2), anti-IL-17 (TC11-18H10.1 or
eBio17B7), anti-IL-10 (JES5-16E3), anti-IL-2 (JES6-5H4) (pur-
chased from eBioscience or BD Bioscience) as described above.
Data was acquired on FACSCanto (Becton Dickinson, Mountain
View, CA) and analysed using FlowJo software (Tree Star).
In vivo therapy
In vivo IL-2 treatment was performed by i.p. injection of 5, 10 or
50 ng of recombinant human IL-2 (rhIL-2) (a kind gift from the
Surgery Branch, NCI). In vivo rapamycin treatment (0.8 mg/kg)
(Sigma) was performed by every other day i.p. injection starting
one day post T cell-adoptive transfer.
In vitro T cell functional assay
For in vitro proliferation, 5610
4 FACS-sorted T cells were plated
with 2610
5 irradiated total splenocytes and activated with soluble
anti-CD3 (1 mg/ml) in the presence or absence of IL-2 (100 u/ml).
For suppression assays, 5610
4 FACS-sorted CD4
+Foxp3
2 (GFP
2)
responder T cells were plated alone or together with T cell subsets
at various ratios and activated as described above. For the last
12 hrs of culture,
3H-thymidine (0.5 mCi) was added and its
incorporation was used to assess cell proliferation. To examine
Foxp3 stability, CD4
+ T cell subsets were stimulated with plate-
bound anti-CD3 (5 mg/ml) in the presence of IL-2 (100 m/ml).
Leishmania cultures and infections
Leishmania promastigotes were cultured as previously shown
[32]. Mice were infected with 5610
6 stationary phase WT or
GP63
2/2 (a gift from W.R. McMaster from UBC, Vancouver)
[33] L. major into the right hind footpad. Disease progression was
assessed and presented as a delta footpad swelling calculated by
subtracting the measurement of infected footpads from non-
infected footpads.
Sodium bisulfite mapping of DNA methylation
EpitectBisulfiteKits(Qiagen)wereusedforbisulfiteconversionof
DNA as described in the manufacturer’s manual. Briefly, samples
were prepared by performing nested PCR with one of the nested
primers carrying a 59 biotin modification. Primers (IDT Technol-
ogies) designed against bisulfite-converted DNA and targeting the
TSDR locus were: outside – TTGAAGATTTAAGGGGGTTT-
TAAT(forward),ACAAATAATCTACCCCACAAATT(reverse);
nested – GGTTTTTTTGGTATTTAAGAA AGA (forward),
biotinylated – CAAATAATCTACCCCACAAATTTC (reverse).
PCRconditionsconsistedofinitialdenaturation/enzymeactivation
at 95uC for 3 min, 40 cycles of 95uC for 30 sec with a respective
annealing temperature of 72uC for 30 seconds, and completed with
a final extension step at 72uC for 4 minutes. Pyro Sequencing was
then performed using a PyroMark Q24 machine according to the
manufacturer’s manual. Briefly, nested PCR products were
incubated with sepharose beads (GE Healthcare) and agitated for
5 minutes,thenwashedin70%ethanol,denaturedin0.2 MNaOH
and mixed with an annealing solution containing the relevant
sequencing primers: region 1 – TTGGTATTTAAGAAAGATAG
and region 2 – TAT TATTTTATTTGGGTTTA. The samples
were then processed by the Pyro Sequencer, and the resulting
percentagemethylationatthetargetedCpGsitescalculatedwiththe
accompanying software (PyroMarkH Q24 Software).
Statistical analysis
Analyses were performed with a Student’s t test. Values of
p,0.05 were considered significant.
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Loss of Foxp3 expression in thymic or peripheral TREG
cells in lymphopenic hosts is modulated by the
frequency of TEFF but not TREG cells
To evaluate whether Foxp3 expression was stable in TREG cells
in vivo, either FACS purified (purity .98%) CD4
+CD25
+ TREG
cells from GFP transgenic C57BL/6 (GFPtg) mice or CD4
+GFP
+
TREG cells from Foxp3
GFPki reporter mice were introduced into T
cell-deficient TCRb
2/2 recipient mice. As early as 4 days post
adoptive transfer, we observed a significant loss of Foxp3
expression in donor T cells (Fig. 1A). The frequency of Foxp3-
negative TREG cells (Foxp3
+R2) progressively increased from 20%
on day 7 to 80% on day 21 (Fig. 1A), and reached a plateau by 4
weeks. The level of Foxp3 expression in residual Foxp3
+ cells
remained unchanged suggests that the loss of Foxp3 expression in
Foxp3
+R2 cells is not gradual (Fig. 1A).
PeripheralinducedTREG(iTREG)cellshavebeenshowntohavea
less stable phenotype in vitro [34,35], and may represent the major
source of emerging Foxp3
+R2 T cells in the peripheral immune
system [19]. We then assessed whether Foxp3
+ TREG cells from
thymus, the primary developmental site for nTREG cells, possess the
potential to convert into Foxp3
2 cells. To achieve this, we
reconstituted TCRb
2/2 recipients with FACS purified TREG cells
ofperipheralorthymicoriginandthenassessedFoxp3expressionin
transferred TREG cells. A significant proportion of thymus-derived
TREGcellsloseFoxp3expression(Fig.1B)althoughthefrequencyof
Foxp3
+R2 cells was significantly lower compared to peripheral
TREGcells(40%vs70%respectively)(Fig.1B).Therapidemergence
of Foxp3
+R2 cells from donor Foxp3
+ TREG cells was not the
consequence of an outgrowth of residual Foxp3
2 T cells present in
transferred TREG cells, as deliberate seeding with 1–3% of
CD4
+Foxp3
2TEFFcellsdidnotchangethefrequencyofFoxp3
+R2
T cells (data not shown). Moreover, our data indicate that the
emergence of Foxp3
+R2 T cells was not caused by a reduced
proliferative capacity of Foxp3
+ TREG cells, as the Foxp3
+R+ cells
cycled similarly to Foxp3
+R2 T cells (Fig. 1C).
We then determined whether the degree of total immune
reconstitution or the TEFF/TREG ratio in the peripheral repertoire
contributes to the loss of Foxp3 expression. To this end, we
introduced FACS purified TREG cells in the presence of titrated
numbers of congenic Ly5.1
+ TEFF cells into TCRb
2/2 recipients
and then assessed Foxp3 expression in transferred TREG cells. Co-
transfer of TEFF cells significantly halts the down-regulation of
Foxp3 expression in TREG cells in a dose dependent manner
(Fig. 1D). At a physiological 10:1 TEFF/TREG cell ratio, the
frequency of Foxp3
+R2 cells decreased from 70% to 30%,
reaching a maximal reduction at a 100:1 TEFF/TREG cell ratio
(Fig. 1D). The frequency of Foxp3
+R2 T cells at 100:1 and 200:1
TEFF/TREG cell ratio remained unchanged. We then asked
whether the nature of the T cell subset in the reconstituted host
influenced the magnitude of Foxp3 downregulation in TREG cells.
To gain insight into this question, GFPtg TREG cells (0.3610
6)
were transferred in TCRb
2/2 recipients alone or in the presence
of CD4
+CD25
2 TEFF, CD4
+CD25
+ TREG or total CD4
+ T cells
(10610
6 each). The presence of TREG cells, in contrast to TEEF
Figure 1. Loss of Foxp3 expression in thymic or peripheral TREG cells in lymphopenic hosts is modulated by the frequency of TEFF
cells, not TREG cells. (A–C) TCRb
2/2 mice received GFPtg CD4
+CD25
+ TREG cells (0.3610
6), and 7, 14 and 21 days post transfer, donor GFP
+ T cells
from mesLN were examined for Foxp3 expression. Representative histograms of Foxp3 expression and percentage of Foxp3
+ cells within GFP
+CD4
+
TREG cells (A) and proportion of cycling cells (Ki-67 expression) within Foxp3
+ or Foxp3
2 donor GFP
+CD4
+ T cells (C) at various time points are shown.
(B) TCRb
2/2 mice received either thymus- or LN- derived GFP
+CD4
+CD25
+ TREG cells. The percentage of Foxp3
+/2 cells within GFP
+CD4
+ T cells is
shown 14 days post adoptive transfer. (D–E) Recipients received GFPtg CD4
+CD25
+ TREG cells (0.3610
6) either alone or in combination with indicated
numbers of CD4
+CD25
2 TEFF, CD4
+CD25
+ TREG or total CD4
+ T cells. 14 days post T cell transfer cells, mesLN were analyzed for Foxp3 by flow
cytometry. The percentage of Foxp3
+ or Foxp3
2 cells within donor GFP
+CD4
+ T cells is shown. Results are representative of 2 to 4 independent
experiments (n=3–4) are shown as mean 6 SEM.
doi:10.1371/journal.pone.0035572.g001
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expression in TREG cells (Fig. 1E).
Collectively, our results show that highly purified TREG cells
from peripheral lymphoid tissues, and particularly from thymic
origin, readily down-regulate Foxp3 expression in the lymphope-
nic environment, a process modulated by the degree of TEFF cell
occupancy in the periphery.
Foxp3
+R2 TREG cell phenotype is stable and correlates
with a methylated Foxp3 promoter
We then sought to determine whether the Foxp3
+R2 T cell
phenotype is stable in vitro and in vivo. To this end, we FACS
purified Foxp3
+R2 and Foxp3
+R+ T cells from recipient mice,
and then examined the level of Foxp3 expression after in vitro TCR
re-stimulation under undifferentiated conditions (Fig. 2A). Neither
of the fractions showed a significant change in their phenotype
after 4 days of culture (Fig. 2A). Although Foxp3
+R2 T cells re-
acquired some Foxp3 (GFP) expression, this induction was
nonetheless minor (1–3%) in this system.
In order to assess the stability of their phenotype in vivo,
Foxp3
+R2 and Foxp3
+R+ T cells were isolated from the first
recipients and re-transferred into secondary TCRb
2/2 recipients.
Freshly-isolated Foxp3
+ and Foxp3
2 T cells from Foxp3
GFPki mice
were used as control cells. Upon secondary adoptive transfer, the
majority of Foxp3
+R+ cells lose their Foxp3 expression (data not
shown), similarly to freshly-isolated TREG cells, suggesting that the
capacity to convert into conventional T cells is a universal feature
of total Foxp3
+ TREG cells rather than the unique potential of a
distinct Foxp3
+ T cell subset as was recently suggested [19].
Interestingly, 15–20% of Foxp3
+R2 T cells re-expressed Foxp3 in
different secondary lymphoid tissues examined, a percentage that
is greater than the frequency of Foxp3
+ cells (,5%) in recipients
reconstituted with freshly-isolated TEFF cells (Fig. 2B). These data
indicate that the Foxp3
+R2 cell population has a stable phenotype
in vivo, although a subset of these cells can regain Foxp3 expression.
The establishment of the stable Foxp3
+ TREG cell lineage
requires selective demethylation of CpG motifs in an evolution-
arily conserved element within the foxp3 locus named TSDR
(TREG-specific demethylated region) [15,36], and this epigenetic
imprinting in the TSDR is completely lost in Foxp3
2 TEFF cells.
To establish whether Foxp3
+R2 T cell fraction demonstrate
different epigenetic modifications compared to naive Foxp3
2 or
Foxp3
+R+ T cells, we performed bisulphite sequencing of eight
evolutionarily conserved CpG motifs within the TSDR of different
T cell population isolated from recipient mice following adoptive
T cell transfer (Fig. 2C), as reported previously [36]. Importantly,
our data shows that all eight CpG motifs of the TSDR are
methylated in Foxp3
+R2 T cells (data not shown), in contrast to
Foxp3
+R+ T cells isolated from the same recipient mice. The total
TSDR methylation status (averaged from eight different sites)
resembles that of freshly-isolated Foxp3
2 TEFF cells or in vivo
activated Foxp3
2R2 TEFF cells (Fig. 2C), confirming that Foxp3
promoter methylation underlies the stable phenotype of
Foxp3
+R2 TREG cells in vivo.
Foxp3
+R2 T cells lose their TREG cell phenotype and
reprogram into Th1 and Th17 effector cells in
lymphopenic hosts
We then investigated whether the loss of Foxp3 led to a
deficiency in TREG cell function. To this end, we tested their
capacity to respond to TCR-induced proliferation and suppressive
function in vitro. Foxp3
+R2 T cells proliferated in vitro with a
slightly greater rate than freshly-isolated TEFF cells even in the
absence of exogenous IL-2 (Fig. 3A). In contrast, Foxp3
+R+ cells
retained their unresponsiveness to TCR-induced proliferation
(anergy), and proliferated only in the presence of exogenous IL-2
(Fig. 3A). More importantly, Foxp3
+R2 cells completely lost their
suppressive function in vitro in contrast to Foxp3
+R+ cells, which
efficiently suppressed proliferation of responding TEFF cells
(Fig. 3B). Furthermore, adoptive transfer of Foxp3
+R2 cells into
Figure 2. The Foxp3
+R2 TREG cell phenotype is stable and correlates with a methylated Foxp3 promoter. TCRb
2/2 mice received
CD4
+GFP
+ T cells (0.5610
6) from Ly5.1
+ congenic Foxp3
GFP reporter mice. Ly5.1
+CD4
+GFP
+ (Foxp3
+) or GFP
2 (Foxp3
2) cells were sorted from
lymphoid tissues of recipient mice 14 days post transfer. (A) Sorted populations were activated in vitro with plate-bound anti-CD3 for 5 days or (B–C)
re-introduced into secondary TCRb
2/2 recipient mice. Freshly-isolated CD4
+GFP
+/2 T cells from Ly5.1
+Foxp3
GFP mice were used as controls. 14 days
post secondary transfer, donor Ly5.1
+CD4
+ T cells from lymphoid tissues of secondary recipient mice were (B) re-analyzed for Foxp3 expression or (C)
sorted according to GFP expression and total genomic DNA was subjected to methylation analysis of Foxp3 promoter region. The percentage of
Foxp3
+ or Foxp3
2 cells within indicated donor T cell populations is shown in (B) as mean 6 SEM (n=3). (C) For each donor T cell population the
percentage of methylated CpG motifs within Foxp3 promoter region was examined at eight different sites and averaged.
doi:10.1371/journal.pone.0035572.g002
Functional Plasticity of Natural Treg Cells in vivo.
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35572lymphopenic hosts led to a significant lymphocytic infiltration in
the colon in contrast to the Foxp3
+R+ cell transfer (data not
shown). These results indicate that Foxp3
+R2 T cells lose the bona
fide TREG phenotype, and gain the behaviour of conventional TEFF
cells in vitro and in vivo.
To further examine whether Foxp3
+R2 cells can acquire
functional properties of TEFF cells, LN cells from TCRb
2/2
recipient mice reconstituted with FACS-purified Foxp3
+ TREG
cells were re-stimulated ex vivo with PMA and ionomycin and
analyzed for the production of pro-inflammatory cytokines relative
to Foxp3 expression (Fig. 3C). We show that over 30% of
Foxp3
+R2 T cells produced high levels of IL-2, IFN-c and IL-17
and show a decreased production of IL-10 in contrast to
Foxp3
+R+ cells which show low frequencies of IL-2 and IFN-c
secreting T cells (,5% and 10% respectively). Although the
frequency of IL-17-producing cells within stable Foxp3
+R+ TREG
cell fraction was comparable to Foxp3
+R2 T cells (up to 30%), the
magnitude of cytokine expression (i.e. MFI) was significantly lower
in Foxp3
+R+ cells (Fig. 3C). Thus, Foxp3 down-regulation in
committed TREG cells impacts their cell fate and differentiation,
and forces their reprogramming into Th1 and Th17 effector cells
in lymphopenic hosts.
Intestinal inflammation or parasitic infection favours the
reprogramming of Foxp3
+ TREG cells into effector T cells
and promotes host immunity
We then compared Foxp3 expression in donor TREG cells from
different lymphoid tissues. We observed a 2–3 fold reduction in the
conversion of Foxp3
+ TREG cells into Foxp3
2 T cells in perLN
compared to mesLN of recipient mice (20–30% vs 80%) (Fig. 4A).
Furthermore, the greatest Foxp3 down-regulation in donor TREG
cells was observed in LP as the frequency of Foxp3
+R2 T cells in
this site reached 90% (Fig. 4A). These data suggest that the
intestinal microenvironment is conducive for the conversion of
Foxp3
+ TREG cells into conventional Foxp3
2 T cells. A distinct
characteristic of mucosal tissues is the constant stimulation of the
local immune system with bacterial antigens. Notably, TCRb
2/2
mice are known to manifest spontaneous inflammation specifically
in the intestine in the absence of any immune reconstitution.
Moreover, this inflammatory response is known to be driven by
the intestinal flora [37]. The analysis of inflammatory cytokines at
the different sites upon TREG cell transfer shows a 2- and 8-fold
increase of total IL-17 and IFN-c secretion, respectively, in
mucosa associated tissues compared to perLN (Fig. 4B). This
suggests that the increased production of inflammatory cytokines
in the gut correlates directly with an increased down-regulation of
Foxp3 in donor TREG cell population in mesenteric sites.
To directly assess the role of local, microbial-induced inflam-
mation in TREG cell reprogramming, we used a model of
cutaneous L. major infection. To this end, we inoculated
intradermally L. major promastigotes into the right hind footpad
of TCRb
2/2 mice, and adoptively transferred GFPtg TREG cells 2
weeks post-infection. While control non-infected popliteal LN
(popLN) show a similar frequency of Foxp3
+R2 T cells compared
to perLN in infected mice (,20%), we observe a dramatic increase
in Foxp3
2 T cells in infected draining LN as 65% of donor TREG
cells down-regulated Foxp3 expression (Fig. 4C). Interestingly, L.
major infected sites show a comparable frequency of Foxp3
+R2
cells compared to mesLN (Fig. 4C) suggesting that microbial-
induced inflammation drives TREG cell reprogramming.
We then determined whether the level of microbial-induced
inflammation in the local TREG environment influences the extent
of TREG cell reprogramming. To achieve this, we compared
Foxp3 expression in donor TREG cells in recipient mice infected
either with a WT strain of L. major or a mutant strain lacking GP63
(GP63
2/2), a key virulence factor directly involved in parasite-host
interactions, and promoting Th1 immune responses in the infected
host. Thus, GP63
2/2 L. major are less infectious and trigger
attenuated inflammatory responses in vivo.
Infection with GP63
2/2 L. major resulted in reduced footpad
swelling compared to WT strain (Fig. 4D) and resulted in minimal
leukocyte infiltration and IFN-c production, which was compara-
ble to non-infected recipients (Fig. 4E, F). We observed that the
frequency of Foxp3
+R2 GFP
+ T cells in draining popLN of
GP63
2/2 L. major infected mice was 2-fold lower compared to WT
L. major infected recipients (35% vs 70% respectively) and slightly
higher compared to non-infected recipients (35% vs 20%
respectively) (Fig. 4G). In addition, we show that the increased
magnitude of Foxp3 down-regulation correlates with a signifi-
cantly higher proportion of IFN-c secreting T cells in L. major
infected sites, in stark contrast to non-infected LN (Fig. 4F)
demonstrating that attenuated inflammatory conditions result in
significantly reduced Foxp3 loss in donor TREG cells. Overall, our
results show a direct, magnitude-dependent role of microbial-
induced inflammatory signals in the down-regulation of Foxp3
expression and reprogramming in donor TREG cells.
Figure 3. Foxp3
+R2 T cells lose their TREG cell phenotype and
reprogram into Th1 and Th17 effector cells in lymphopenic
hosts. (A–B) TCRb
2/2 mice received CD4
+GFP
+ TREG cells (0.5610
6)
isolated from Foxp3
GFP reporter mice, and 14 days later, donor
CD4
+GFP
+(Foxp3
+)/GFP
2(Foxp3
2) cells were sorted from recipient mice
and their proliferation (A) and suppressive activity (B) were assessed
following in vitro activation. Freshly isolated TREG and TEFF cells from
Foxp3
GFP mice were used as controls. Data from one of three
independent experiments is presented as mean 6 s.d. of triplicate
wells. (C) TCRb
2/2 mice received GFPtgCD4
+CD25
+ TREG cells (0.3610
6),
and 14 days post transfer, GFP
+ donor T cells were examined for the
production of various cytokines relative to Foxp3 expression. Frequen-
cies and mean fluorescent intensity (MFI) (C) of cytokines produced by
Foxp3
+/2 cells are shown as mean 6 SEM from one out of 4
independent experiments (n=4).
doi:10.1371/journal.pone.0035572.g003
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variations in IL-2 production in vivo
One critical factor responsible for the development, function
and homeostasis of Foxp3
+ TREG cells is IL-2, a cytokine primarily
produced by activated TEFF cells. Fluctuations in the bio-
availability of IL-2 in inflammatory sites may perturb the TREG/
TEFF balance in these sites and trigger autoimmunity [38–41].
Duarte et al. [20] recently showed that prophylactic IL-2 infusion
in vivo can prevent Foxp3 down-regulation in TREG cells suggesting
that a temporal deficiency in IL-2, possibly as a consequence of the
absence of TEFF cells, was the initial trigger for Foxp3 loss in TREG
cells. However, in our system, the delivery of high (50 ng) or low
(5 ng) doses of rhIL-2, previously shown to be favourable for the
homeostasis of Foxp3
+ TREG cells and protection from autoim-
mune diabetes [40], failed to prevent the loss of Foxp3 expression
in donor TREG cells in all tissues examined (Fig. 5A). Moreover,
the time or frequency of treatment initiation did not change the
outcome (data not shown). Interestingly, both low and high IL-2
dose treatments resulted in a significant increase in CD25
expression (MFI) and frequency of CD25
+ cells solely within the
stable Foxp3
+R+ T cell fraction but not in Foxp3
+R2 cells
(Fig. 5B). This suggests that Foxp3
+R+ T cells may be particularly
sensitive to IL-2 signals in vivo.
We then assessed how the production of IL-2 in vivo related with
the onset and magnitude of Foxp3 loss in donor TREG cells. Our
earlier results show that unlike stable Foxp3
+R+ TREG cells, around
30% of Foxp3
+R2 T cells in mesenteric LN (mesLN) secrete IL-2
(Fig. 3C) as soon as they are detected in the system (Fig. 5C).
Interestingly, we show a 2-fold increase in the frequency of IL-2
+
Foxp3
+R2 T cells in mesLN compared to perLN (Fig. 5D) despite
the more significant loss of Foxp3 in donor TREG cells in mucosa-
drainingLN.Thus,themagnitudeofFoxp3lossindonorTREGcells
inversely correlated with the frequency of IL-2 secreting Foxp3
+R2
CD4
+ T cells. Overall, these results indicate that Foxp3 down-
regulation indonor TREG cells is not triggered solely by a deficiency
in T cell-derived IL-2 in secondary lymphoid tissues.
Predominant IL-17 secretion precedes Foxp3 down-
regulation in reprogramming Foxp3
+ TREG cells, a process
accentuated in mesenteric sites
To assess whether cellular expansion contributed to Foxp3
down-regulation in TREG cells, the level of Foxp3 expression in
donor CFSE-labelled CD4
+CD25
+ TREG cells was determined 3,
4, 5 and 10 days post adoptive cell transfer (Fig. 6A). Our analysis
shows that Foxp3
+R2 T cells emerge already by 3 days post T cell
transfer in the mesLN, and Foxp3 down-regulation occurs only in
actively proliferating T cells (Fig. 6A). Interestingly, we observed a
delay in the emergence of Foxp3
+R2 T cells in perLN compared
to mesLN, although the proportion of divided donor T cells in
both lymphoid tissues was similar (51% vs 39% at day 3 and 80%
vs 80% at day 4) (Fig. 6A). This finding strongly suggests that
Foxp3 down-regulation in donor TREG cells is only partly
attributed to the homeostatic proliferation during lymphopenia.
A kinetic analysis of cytokine production by Foxp3
+R2 and
Foxp3
+R+ T cells revealed prominent IL-17 secretion, which
temporally preceded IFN-c production in both fractions of donor
TREG cells (Fig. 6B–E). The predominant IL-17 secretion was
particularly marked in Foxp3
+R2 T cells in mesLN (Fig. 6C, E).
Figure 4. Intestinal inflammation or parasitic infection favours the reprogramming of Foxp3
+ TREG cells into effector T cells and
promotes host immunity. (A–B) TCRb
2/2 mice received GFPtg CD4
+CD25
+ T cells (0.3610
6). 14 days later Foxp3 expression within donor
GFP
+CD4
+ T cells (A) and the frequency of total IFN-c or IL-17 producing cells (B) in indicated tissues of recipient mice from one of 3 representative
experiments (n.3) is shown. (C–G) TCRb
2/2 mice were infected or not (NI) with 5610
6 promastigotes of WT or GP63
2/2 (KO) L. major into the right
footpad 2 weeks prior reconstitution with GFPtgCD4
+CD25
+ TREG cells (0.3610
6). (C) 4 weeks later, GFP
+CD4
+ T cells from draining (infected) and non-
draining popliteal LN, perLN and mesLN were analyzed for Foxp3 expression. Footpad swelling (D), absolute number of infiltrated lymphocytes (E),
and frequencies of IFN-c producing CD4
+ T cells (F) are shown in infected and non-infected sites. (G) The loss of Foxp3 expression by TREG cells was
compared between mice infected with WT or GP63
2/2 L. major strains. Results are representative of 2 independent experiments with n=4–5.
doi:10.1371/journal.pone.0035572.g004
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+R2 T cells
secreted IL-17 and only 10% secreted IFN-c. Interestingly, while
the proportion of IFN-c producing Foxp3
+R2 and Foxp3
+R+ T
cells increased with time, reaching respectively 30% and 10% at
day 10, the proportion of IL-17
+ cells did not vary (Fig. 6C, E),
suggesting a bias for IL-17-polarization in reprogrammed
Foxp3
+R2 T cells.
To establish whether Th17-like Foxp3
+R2 T cells display a
phenotype reminiscent of conventional Foxp3
2 TEFF cells, the
cytokine profile of Foxp3
+R2 and Foxp3
2R2 T cell populations
was determined upon secondary adoptive T cell transfer into new
TCRb
2/2 recipients. Our data show that 14 days post secondary
T cell transfer, re-programmed Foxp3
+R2 T cells maintained
their phenotype and contained 2-fold higher proportion of IL-17
producing cells compared to Foxp3
2R2 T cells (Fig. 6F).
Interestingly, Foxp3
+R2 T cells still produced a comparable
amount of IFN-c compared to conventional Foxp3
2 TEFF cells
(Fig. 6F), suggesting that the re-programmed Foxp3
+R2 T cells
display a more pro-inflammatory IL-17-dominant phenotype.
mTOR inhibition stabilizes Foxp3 expression in TREG cells
and strongly inhibits IL-17 but not ROR-ct expression in
vivo
Rapamycin is an immunosuppressive drug which inhibits the
mTOR signalling pathway and selectively promotes Foxp3
+ TREG
lineage differentiation in vitro and in vivo, while inhibiting the
differentiation of Foxp3
2 TEFF cells [25,42]. In order to examine
whether Foxp3 down-regulation in donor TREG cells is mTOR
pathway dependant, TCRb
2/2 recipient mice were treated with
rapamycin every other day after Foxp3
+ TREG cell transfer, and
donor T cells from mesLN and perLN were analyzed for Foxp3
expression 7 and 14 days later. Our data show that while
rapamycin did not have any effect on the level of Foxp3 expression
in donor TREG cells in perLN, it potently inhibited Foxp3 down-
regulation in mesLN 14 days post adoptive transfer, consequently
rescuing the proportion of Foxp3
+ donor TREG cells from 27% up
to 55% (Fig. 7A). We also observed a significant decrease in IL-17-
producing donor T cells following in vivo rapamycin treatment,
whereas the frequency of IFN-c secreting T cells remained
unchanged (Fig. 7B). Reprogrammed Foxp3
+R2 T cells in both
perLN and mesLN showed the most marked decrease (4-fold) in
the proportion of IL-17-secreting T cells (Fig. 7B). These results
are consistent with previous studies illustrating rapamycin-
mediated inhibition of Th17 cells [28].
As RORct is a critical factor for Th17 cell development, we
hypothesized that inhibition of the mTOR pathway would prevent
IL-17 secretion by abrogating RORct expression. Surprisingly,
rapamycin treatment did not alter RORct expression either in re-
programmed Foxp3
+R2 or in stable Foxp3
+R+ T cells (Fig. 7C),
suggesting that inhibition of the mTOR pathway selectively
influences other factors involved Th17 cell differentiation. Thus,
rapamycin-mediated inhibition of mTOR activity stabilizes the
Foxp3
+ TREG cell pool, particularly in inflammatory mesenteric
sites, and strongly inhibits Th17 cell development in vivo.
Discussion
It is commonly viewed that Foxp3-expressing T cells represent a
stable, terminally-differentiated lineage responsible for suppression
of a wide variety of immune responses and maintenance of
peripheral self-tolerance. Recently, studies proposed that Foxp3
+
TREG cells, or an unstable subpopulation found within, retains
developmental plasticity, whose modulating factors have yet to be
clearly elucidated [19–21].
Here, we show that thymic and peripheral Foxp3
+ TREG cells of
normal, unmanipulated mice possess the potential to lose Foxp3
expression in vivo. This reprogramming of TREG cells provokes the
loss of the bona fide Foxp3
+ TREG cell phenotype and re-directs
their effector differentiation primarily to Th1 and Th17 cell
lineages. Further in vitro and in vivo comparison of Foxp3
+R2 and
naı ¨ve Foxp3
2 TEFF cells revealed the strong similarities in their
phonotypical and functional characteristics as well as epigenetic
modifications of Foxp3 promoter region. The fact that Foxp3
+R2
T cells produce more IL-17 upon secondary adoptive transfer into
lymphopenic host compared to naı ¨ve Foxp3
2 T cells, suggests a
possible bias for Th17 polarization in unstable Foxp3
+R2 TREG
cells. Moreover, our data propose that IL-17
+Foxp3
+ T cells,
which are found in secondary lymphoid organs of recipient mice,
may possibly represent a transitional stage of Foxp3
+ TREG cells
converting to Foxp3
+R2 T cells.
We show that reprogrammed Foxp3
+R2 TREG cells manifest a
stable phenotype following TCR re-activation in un-polarized
conditions in vitro and after extensive cell division in lymphopenic
hosts. This is in contrast to a recent study showing that
reprogrammed Foxp3
+R2 TREG cells have the potential to
reacquire Foxp3 expression under TGF-b1 inducing conditions
[19]. Only around 20% of Foxp3
+R2 T cells regain Foxp3
expression suggesting that TCR re-activation in Foxp3
+R2 T cells
does not re-establish the ‘‘memory’’ of original Foxp3 expression
Figure 5. TREG cell reprogramming occurs independently of variations in IL-2 production in vivo. (A–B) TCRb
2/2 mice were treated every
other day with 5 or 50 ng of rhIL-2, starting 2 days prior transfer of GFPtg CD4
+CD25
+ T cells (0.3610
6). MesLN were analyzed for Foxp3 expression 14
days later. The percentage of Foxp3
+/2 cells (A) and the frequency of CD25
+ cells and MFI of CD25 expression (B) within donor GFP
+CD4
+ T cells are
shown. (C–D) TCRb
2/2 mice received GFPtg CD4
+CD25
+ T cells (0.3610
6). Donor T cells from perLN and mesLN were analyzed for Foxp3 expression
and IL-2 production. (C) The frequency of IL-2 secreting GFP
+CD4
+Foxp3
2 T cells and (D) correlation between frequency of IL-2
+ and Foxp3
2 cells
within donor GFP
+CD4
+ T cells is shown. Results are representative of 2 independent experiments (n=3–4).
doi:10.1371/journal.pone.0035572.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35572in parent cells by enabling de novo active transcription at the
remodelled foxp3 locus [15].
We show that while Foxp3 loss is primarily seen in actively
dividing TREG cells in lymphopenic mice, the pre-existing TEFF/
TREG ratio is an important variable in Foxp3
+R2 T cell
generation. We observe that the increased frequency of total or
effector CD4
+ T cells co-transferred with TREG cells reduces the
magnitude of the loss of Foxp3 expression in TREG cells. The
minimal loss of Foxp3 expression (15%), achieved at high 100:1
TEFF/TREG ratio, correlates with the basal level of the Foxp3
down-regulation detected in normal lymphoreplete mice [22],
suggesting that the degree of total reconstitution in lymphopenic
hosts prevents Foxp3 loss. Moreover, co-transfer of similar
numbers of TREG cells does not modulate the level of Foxp3
down-regulation, suggesting that the total degree of Foxp3 loss
may correlate with a lack of occupancy of TEFF cell niches or TEFF
derived signals.
The particular TEFF cell-mediated signals that stabilize Foxp3
expression are still unknown. IL-2, a likely candidate, was recently
shown to prevent Foxp3 down-regulation in TREG cells suggesting
that a temporal deficiency in IL-2, possibly as a consequence of the
absence of TEFF cells in the periphery, was the initial trigger for
Foxp3 loss in TREG cells [20]. Several lines of evidence from our
study do not support a causative role for an IL-2 deficiency in the
generation of Foxp3
+R2 T cells. We show that the magnitude of
Foxp3 loss in donor TREG cells inversely correlated with the
frequency of IL-2 secreting Foxp3
+R2 CD4
+ T cells suggesting
that Foxp3 down-regulation is not triggered solely by a deficiency
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Figure 6. Predominant IL-17 secretion precedes Foxp3 down-regulation in reprogramming Foxp3
+ TREG cells, a process
accentuated in mesenteric sites. (A–E) TCRb
2/2 mice received CFSE-labelled CD4
+CD25
+ T cells (0.3610
6) isolated from congenic Ly5.1
+
mice, and, donor T cells were examined for Foxp3 expression at the indicated timepoints post transfer. (A) Representative FACS plots of Foxp3
expression relative to CFSE dilution in donor Ly5.1
+CD4
+ T cells are shown at various time points. (B–E) Representative FACS profiles (B,C) and
proportion (D,E) of IL-17/IFN-c-secreting donor Ly5.1
+CD4
+Foxp3
+ (B,D) and Foxp3
2 (C,E) T cells undergoing expansion at various time points are
shown. Results are representative of 2 independent experiments (n=3). (F) TCRb
2/2 mice received CD4
+GFP
+ T cells (0.5610
6) isolated from Ly5.1
+
congenic Foxp3
GFP reporter mice, 14 days post transfer Ly5.1
+CD4
+GFP
2 cells (Foxp3+R2) were sorted from lymphoid tissues of recipient mice, and
reintroduced into secondary TCRb
2/2 recipient mice. Freshly-isolated CD4
+GFP
2 T cells (Foxp3-) from Ly5.1
+Foxp3
GFP mice were used as a control. 14
days post secondary transfer, donor Ly5.1
+CD4
+ T cells from mesLN of secondary recipients were analyzed for IL-17/IFN-c secretion relative to Foxp3
expression. Proportion of cytokine producing Foxp3
2Ly5.1
+CD4
+ T cells is shown as mean 6 SEM from one out of 2 independent experiments (n=4).
doi:10.1371/journal.pone.0035572.g006
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35572in T cell-derived IL-2 in secondary lymphoid tissues. Moreover,
both low and high dose prophylactic IL-2 treatments resulted in a
significant increase in CD25 expression and frequency of CD25
+
cells only within the stable Foxp3
+ T cell fraction suggesting that
IL-2 preferentially favours the fitness of stable Foxp3
+R+ TREG
cells without preventing TREG cell reprogramming.
The greatest degree of TREG cell plasticity was observed in the
gut microenvironment, and reprogramming of TREG cells
associated with significantly higher production of pro-inflamma-
tory cytokines, particularly IL-17, in mesenteric sites. The more
elevated basal inflammation induced by the constant exposure to
commensal microbes coincides with the magnitude of Foxp3
+R2
cell reprogramming. This correlates with the recently published
study indicating the gastrointestinal tract is a specific site for
generation and control of Th17 cells [43]. Moreover, the locally
induced infection with WT or attenuated form of L. major directly
confirms that the magnitude of pathogen-induced inflammation is
a critical factor in the emergence of TEFF cells from Foxp3
+ TREG
cell population. The possibility of concomitant recruitment of
reprogrammed Foxp3
+R2 cells to inflammatory sites from other
lymphoid sites cannot be excluded. While the nature of the innate
signals remain unidentified, the substantial emergence of IL-17
producing cells in both Foxp3
2 and Foxp3
+ fractions of donor
TREG cells indicates the involvement of Th17 promoting factors in
generation of Foxp3
+R2 T cells. In vitro, IL-6 inhibits Foxp3
expression in vitro [18] and, in combination with TGF-b, promotes
the generation of IL-17 producing cells from conventional [44,45]
or regulatory T cells [16,17]. Recently, it was shown that L. major
infection triggers IL-6 secretion in DC [46] and keratinocytes [47],
and that IL-6 neutralization, together with an exacerbated L.
major-induced pathology, increased local TREG cell numbers in the
site of infection [48]. Thus, these data suggest a role for Th17
polarizing factors not only in anti-parasitic immunity but also in
the reprogramming of TREG cells into Foxp3
2 TEFF cells.
The PI3K/Akt pathway primarily signals through the mTOR,
a master regulator that integrates metabolic, environmental and
inflammatory cues, which ultimately promotes cell growth,
proliferation, and T cell differentiation. More specifically, PI3K/
Akt/mTOR signalling abrogates TREG cell differentiation, and
over-expression of an active form of Akt abrogates TGF-b-induced
Foxp3 expression in CD4
+ T cells [26,49]. Our results
demonstrate that mTOR inhibition by rapamycin, prevents
Foxp3 down-regulation, stabilizes the Foxp3
+ TREG cell pool,
particularly in the inflammatory gut microenvironment, and
strongly inhibits TREG cell reprogramming into Th1 and Th17
effectors in vivo. These results are consistent with previous studies
showing that similar inhibition of mTOR signalling, either
through genetic deletion or rapamycin treatment, promotes TREG
differentiation while blunting TEFF cell differentiation and function
in vitro and in vivo [25,27]. Furthermore, we show that Foxp3
+
TREG cells readily express significant levels of RORct, as
confirmed by previous studies [50,51], and indicates that
rapamycin-mediated inhibition of IL-17 production by re-
programmed Foxp3
+R2 T cells does not correlate with a
reduction in RORct expression and may selectively influence
other factors involved Th17 cell differentiation. Overall, our
results suggest that changes in metabolic, inflammatory or
environmental signals within the TREG cell microenvironment
modulate mTOR function, and may impact the stability of the
Foxp3
+ expression and TREG cell function in settings of tolerance
or immunity.
A lingering, controversial question concerns the cellular origin
of newly-generated Foxp3
+R2 T cells. Recently, a study by
Komatsu and colleagues [19] suggests that only a small fraction of
Foxp3
+ nTREG cells, negative for CD25 expression, possesses the
Figure 7. mTOR inhibition stabilizes Foxp3 expression in TREG cells and strongly inhibits IL-17 but not RORct expression. TCRb
2/2
mice were transferred with GFPtg CD4
+CD25
+ TREG cells (0.3610
6), and then treated every second day with rapamycin (R) (18 mg/kg) or control
vehicle (formulation without rapamycin) (V) as of day 0. 7 and 14 days later, perLN and mesLN of recipient mice were analyzed by FACS. (A) Foxp3
expression within donor GFP
+CD4
+ T cells, (B) proportion of IL-17/IFN-c producing Foxp3
+/2 donor T cells and (C) RORct expression within Foxp3
+/2
donor T cells are shown as mean 6 SD from one out of 2 independent experiments (n=4).
doi:10.1371/journal.pone.0035572.g007
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2 T cells in contrast to the
Foxp3
+CD25
+ cell subset representing a stable TREG population.
In our study we cannot attribute the down-regulation of Foxp3 to
any particular subpopulation of nTREG cells since both
CD4
+CD25
high (excludes CD25
NegFoxp3
+) and CD4
+Foxp3
GFP+
(includes CD25
NegFoxp3
+ and CD25
+Foxp3
+ subsets) subpopula-
tions demonstrate similar ability to lose Foxp3 expression in vivo.
Moreover, the observation that a significant proportion of the
stable Foxp3
+ donor T cells continued to down-regulate Foxp3
expression upon secondary adoptive transfer strongly suggests that
the total Foxp3
+ TREG population rather than a specific fraction
exhibits this functional plasticity.
Overall, the findings of this study highlight the dynamics of
Foxp3 expression in committed Foxp3
+ TREG cells, and point to
the nature and magnitude of inflammation as critical factors
modulating the plasticity of Foxp3
+ TREG cells. As peripheral
Foxp3
+ TREG cells display an augmented potential for Foxp3
down-regulation compared to thymus-derived Foxp3
+ T cells,
caution should be taken in designing future therapeutic studies
involving TREG cell infusions. However, as no inflammation or
disease induction was observed in TREG cell-reconstituted
recipient mice even with a maximum degree of Foxp3 down-
regulation, this may suggest that the consequence of this TREG cell
plasticity is to ensure the occupancy of the conventional T cell
niche by Foxp3
+R2 T cells in the lymphopenic environment and
maintain a TEFF/TREG equilibrium in the peripheral immune
system.
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